Ministers plan to use NHS app to expand clinical trials as part of UK-wide drive

TruthLens AI Suggested Headline:

"UK Government to Enhance Clinical Trials Through NHS App Integration"

View Raw Article Source (External Link)
Raw Article Publish Date:
AI Analysis Average Score: 8.1
These scores (0-10 scale) are generated by Truthlens AI's analysis, assessing the article's objectivity, accuracy, and transparency. Higher scores indicate better alignment with journalistic standards. Hover over chart points for metric details.

TruthLens AI Summary

The UK government is launching a comprehensive initiative aimed at significantly expanding clinical trials across the nation, leveraging the NHS app to facilitate participation from millions of individuals. This innovative approach will enable patients to be automatically matched to relevant clinical studies based on their health data and personal interests, with notifications sent directly to their smartphones. In a bid to enhance accountability and performance, NHS trusts that do not meet clinical trial targets will be publicly identified, while those that excel will receive prioritized funding. This strategy is among the first to emerge from the government's forthcoming 10-year health plan for England, designed to restore the UK's reputation as a leader in medical research. Streamlining NHS records is a key component of this initiative, which aims to simplify the process of identifying suitable candidates for trials and reducing the bureaucratic hurdles typically associated with clinical studies.

Health Secretary Wes Streeting emphasized the UK's historical significance in scientific and medical advancements, asserting that the NHS app will serve as a 'digital front door' to facilitate public involvement in developing future medicines. The government plans to drastically reduce the time required to set up clinical trials, aiming for a maximum of 150 days by March 2026, in contrast to the current average of 250 days. This push is seen as essential to attract pharmaceutical companies back to the UK, especially in light of a recent decline in patient enrollment in clinical trials. The National Institute for Health and Care Research is actively promoting participation from underrepresented groups, including young people and ethnic minorities, to ensure a diverse pool of trial participants. Amidst criticisms regarding the slow pace of trial launches, the government is determined to revitalize the sector and position the UK as a competitive player in the global life sciences market.

TruthLens AI Analysis

You need to be a member to generate the AI analysis for this article.

Log In to Generate Analysis

Not a member yet? Register for free.

Unanalyzed Article Content

The government is aiming for a significant expansion of clinical trials in the UK, and plans to use the NHS app to encourage millions of people inEnglandto take part in the search for new treatments.

Patients will eventually be automatically matched with studies based on their health data and interests, via the app. The plans envisage alerting them to the trials using smartphone notifications.

NHS trusts that fail to meet targets on trials will also be publicly named, and the best performers will be prioritised for funding, as part of improvements designed to restore Britain’s global reputation for medical research.

The strategy is one of the first to emerge from the government’s forthcoming 10-year health plan for England. It aims to take advantage of changes simplifying NHS records by quickly identifying people suitable for a trial. It will also include measures to streamline the paperwork required for the studies.

It is hoped the reforms will speed up the trials process and attract more pharmaceutical companies to host them in Britain, as ministers in all departments are ordered to find pro-growth measures.

The 10-year health plan will promise to slash set-up times for trials. While it takes about 100 days to set up a trial in Spain, it now takes 250 days in the NHS. The plan will push for commercial clinical trial set-up times to fall to a maximum of 150 days by March 2026.

“The UK has been at the forefront of scientific and medical discovery throughout our history,” saidWes Streeting, the health secretary. “Some country will lead the charge in the emerging revolution in life sciences, and why shouldn’t it be Britain?

“The NHS app will become the digital front door to the NHS, and enable all of us as citizens to play our part in developing the medicines of the future. The British people showed they were willing to be part of finding the vaccine for Covid, so why not do it again to cure cancer and dementia?”

Officials believe the scheme could give the UK an advantage over other countries with insurance-based health systems because of the centralised nature of the NHS.

Under the new system, run on the NHS app by the National Institute forHealthand Care Research’s (NIHR) Be Part of Research service, millions of people will be able to search for and sign up to clinical trials, browsing through them according to their interests or needs.

Sign up toFirst Edition

Our morning email breaks down the key stories of the day, telling you what’s happening and why it matters

after newsletter promotion

TheNIHR has launched a recruitment drive for clinical trials, with underrepresented groups including young people, black people and people of south-Asian heritage particularly encouraged to sign up. The NHS does not compensate volunteers for taking part in clinical trials, but commercial trials often do.

It comes after recent criticisms of the speed of clinical trial launches in the UK. A study last year by the Association of the British Pharmaceutical Industry found that the number of patients entering UK clinical trialsfell by 27% between 2018 and 2023, while new industry trials declined by 38%. The struggles of the NHS and the universities sector, as well as bureaucracy, have all been blamed for the problems.

Last year, John-Arne Røttingen, the chief executive of the Wellcome Trust, which invests more than £1bn a year in UK research, warned that drug companies would “decide to go elsewhere” because of the strains on the NHS.

Back to Home
Source: The Guardian